Canadian biotech company applies for patents on Zika detection method

BioLytical Laboratories has previously developed processes for fast detection of HIV and Ebola viruses

BioLytical’s new Zika detection system is based on of the company’s HIV test, which detects the antibodies that a disease produces. Photo: Nechaevkon/Shutterstock

Richmond-based medical tech company BioLytical Laboratories has filed two patent applications in the US for its new Zika virus detection method.

“It is important to have innovative and relevant technologies at a state of readiness to enable a rapid response to emerging infectious disease like the Zika virus outbreak,” said Rick Galli, the company’s chief technical officer.

Print option is available for subscribers only.
SUBSCRIBE NOW
Copyright © 2025 South China Morning Post Publishers Ltd. All rights reserved.